| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
90,630,000 |
| Market
Cap: |
13.92(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$129.52 - $265 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 664 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
100,397 |
1,200,397 |
5,371,251 |
5,588,274 |
| Total Sell Value |
$15,909,372 |
$214,459,372 |
$1,041,558,017 |
$1,085,894,829 |
| Total People Sold |
2 |
3 |
8 |
9 |
| Total Sell Transactions |
6 |
7 |
21 |
54 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Oyler John |
Chief Executive Officer |
• • – |
2020-09-28 |
4 |
AS |
$278.50 |
$8,682,063 |
D/D |
(31,000) |
0 |
|
32% |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2020-09-25 |
4 |
AS |
$280.29 |
$1,402,116 |
I/I |
(5,000) |
0 |
|
31% |
|
| Wu Xiaobin |
President & GM China |
• – – |
2020-09-25 |
4 |
AS |
$280.35 |
$1,121,406 |
D/D |
(4,000) |
0 |
|
31% |
|
| Wu Xiaobin |
President & GM China |
• – – |
2020-09-17 |
4 |
AS |
$260.20 |
$1,041,327 |
D/D |
(4,000) |
0 |
|
22% |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2020-09-17 |
4 |
AS |
$260.26 |
$1,301,356 |
I/I |
(5,000) |
0 |
|
22% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-09-16 |
4 |
AS |
$253.71 |
$6,948,807 |
D/D |
(27,275) |
0 |
|
25% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-09-15 |
4 |
AS |
$251.39 |
$8,699,381 |
D/D |
(34,214) |
0 |
|
26% |
|
| Liang Howard |
CFO & Chief Strategy Officer |
• – – |
2020-09-14 |
4 |
AS |
$247.46 |
$3,503,764 |
D/D |
(14,000) |
0 |
|
43% |
|
| Liang Howard |
CFO & Chief Strategy Officer |
• – – |
2020-09-14 |
4 |
OE |
$6.50 |
$91,000 |
D/D |
14,000 |
14,000 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-09-14 |
4 |
AS |
$247.01 |
$4,939,782 |
D/D |
(19,739) |
0 |
|
43% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2020-09-03 |
4 |
AS |
$232.25 |
$729,045 |
D/D |
(3,128) |
0 |
|
48% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-09-02 |
4 |
AS |
$224.52 |
$6,374,024 |
D/D |
(27,807) |
0 |
|
43% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-09-01 |
4 |
AS |
$230.87 |
$4,739,809 |
D/D |
(20,274) |
0 |
|
31% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-08-31 |
4 |
AS |
$237.82 |
$3,121,765 |
D/D |
(12,961) |
0 |
|
20% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2020-08-28 |
4 |
AS |
$240.15 |
$726,626 |
D/D |
(3,000) |
0 |
|
15% |
|
| Huang Jane |
CMO, Hematology |
• – – |
2020-08-28 |
4 |
OE |
$29.49 |
$88,470 |
D/D |
3,000 |
3,000 |
|
- |
|
| Amgen Inc |
10% Owner |
– – • |
2020-08-25 |
4 |
A |
$248.49 |
$14,757,578 |
D/D |
59,390 |
18,524,373 |
|
- |
|
| Amgen Inc |
10% Owner |
– – • |
2020-08-24 |
4 |
A |
$239.10 |
$14,199,906 |
D/D |
59,390 |
18,464,983 |
|
- |
|
| Amgen Inc |
10% Owner |
– – • |
2020-08-21 |
4 |
A |
$230.18 |
$14,772,012 |
D/D |
64,176 |
18,405,593 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-08-21 |
4 |
AS |
$237.80 |
$9,796,775 |
D/D |
(40,788) |
0 |
|
12% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-08-20 |
4 |
AS |
$230.16 |
$5,049,749 |
D/D |
(21,523) |
0 |
|
11% |
|
| Amgen Inc |
10% Owner |
– – • |
2020-08-20 |
4 |
A |
$234.99 |
$15,080,981 |
D/D |
64,176 |
18,341,417 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • – |
2020-08-19 |
4 |
AS |
$232.36 |
$7,005,265 |
D/D |
(29,866) |
0 |
|
10% |
|
| Amgen Inc |
10% Owner |
– – • |
2020-08-19 |
4 |
A |
$234.88 |
$15,073,454 |
D/D |
64,176 |
18,277,241 |
|
- |
|
| Amgen Inc |
10% Owner |
– – • |
2020-08-18 |
4 |
A |
$230.18 |
$9,207,188 |
D/D |
40,000 |
18,213,065 |
|
- |
|
241 Records found
|
|
Page 6 of 10 |
|
|
5.02 (3.38%) 
